认知正常老年人对淀粉样蛋白PET生物标志物升高结果的理解
本研究通过对80名参与者(其中50名淀粉样蛋白PET升高)进行电话访谈,评估认知正常老年人对升高结果的理解。结果显示62%的参与者理解升高淀粉样蛋白意味着增加但不确定的AD风险,部分人希望获得更具体的定量信息。建议未来试验和宣教材料应解释生物标志物从维度到分类的转换过程。
要点
- 多数认知正常老年人能理解淀粉样蛋白PET升高代表不确定的AD风险增加。
- 部分参与者希望了解淀粉样蛋白的具体数值或与阈值的距离。
- 解释生物标志物分类依据可提升未来AD试验的沟通效果。
核心结论
- 认知正常老年人对淀粉样蛋白PET升高结果的理解总体较好,但部分人希望获得更详细的定量信息。
研究设计与样本
- 研究为AD预防试验的子研究,对80名参与者(50名淀粉样蛋白PET升高,30名未升高)进行两次半结构化电话访谈,分别于结果披露后4-12周和1年后进行。
主要发现
- 50名淀粉样蛋白PET升高的参与者中,31人(62%)理解升高代表增加但不确定的AD风险。
- 部分参与者希望了解淀粉样蛋白的具体数值、与阈值的距离或百分比等信息。
临床怎么用
- 向认知正常老年人披露淀粉样蛋白PET升高结果时,应提供定量信息并解释分类依据。
局限性
- 研究对象以白人、有AD家族史和高学历者为主,可能限制结果的普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The goal of Alzheimer disease (AD) prevention together with advances in understanding the pathophysiology of AD have led to clinical trials testing drugs in cognitively unimpaired persons who show evidence of AD biomarkers. Data are needed to inform the processes of describing AD biomarkers to cognitively normal adults and assessing their understanding of this knowledge. OBJECTIVE: To determine the comprehension of an elevated amyloid positron emission tomographic (PET) biomarker result by cognitively unimpaired adults. DESIGN, SETTING, AND PARTICIPANTS: The Study of Knowledge and Reactions to Amyloid Testing, a substudy of an AD prevention trial, involved 2 semistructured telephone interviews with 80 participants recruited from 9 study sites: 50 received elevated and 30 received not elevated amyloid PET scan results. Interviews were conducted 4 to 12 weeks after result disclosure and again 1 year later. Data presented here were collected from November 5, 2014, through December 10, 2015. The 50 participants included in this study were cognitively normal, aged 65 to 85 years, evenly distributed by gender, and had elevated amyloid PET results. Subsequent reports will examine persons with "not elevated" results and compare the influence of the different results. MAIN OUTCOMES AND MEASURES: Participant comprehension of an elevated amyloid result was assessed by analyzing their responses to the following questions: "What was the result of your amyloid PET scan?" (followed by "Can you tell me in your own words what that means?" or "How would you explain it to a friend?"), "Was it the result you expected?" and "Did the result teach you anything or clarify anything for you?" RESULTS: Of the 50 participants aged 65 to 85 years, 49 (98%) were white, 40 (80%) reported a family history of AD, and 30 (60%) had a postgraduate educational level. Most participants (31 [62%]) understood that elevated amyloid conferred an increased but uncertain risk of developing AD. Some desired understanding of the term elevated other than its being a categorical result enabling trial entry eligibility; they wanted information regarding how elevated their amyloid was, how close to the study threshold they were, or percentages, numbers, or a scale to help them make sense of the result. CONCLUSIONS AND RELEVANCE: Including an explanation of how and why a dimensional biomarker is converted to a categorical classification would enhance future AD biomarker clinical trials and educational materials.
引用
- Mozersky J, Sankar P, Harkins K, et al. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults. JAMA Neurol. 2018. PMID: 29059270. doi:10.1001/jamaneurol.2017.2954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。